Floatz logo

RANITIDINE

Peritoneal Neoplasm

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Peritoneal Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
AstraZeneca
Phase 2BB
Benadryl
National Cancer Institute (NCI)
Phase 2B
Solu-Cortef
National Cancer Institute (NCI)
Phase 2B
Enzastaurin
Eli Lilly and Company
Phase 2B
Semaxanib
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

RANITIDINE is also rated in:

breast cancerDormant
BB
Indicative ·
64 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
63 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →